Candy Kumps
Overview
Explore the profile of Candy Kumps including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
673
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Rose G, Denys M, Kumps C, Whishaw D, Khan F, Everaert K, et al.
Neurourol Urodyn
. 2019 Jun;
38(6):1648-1656.
PMID: 31165518
Aim: Nocturia frequency has been used as a measure of treatment efficacy for nocturia even though fluctuation of the symptom over time has been well described in the literature. Additionally,...
12.
Claeys S, Denecker G, Durinck K, Decaesteker B, Mus L, Loontiens S, et al.
Oncogene
. 2018 Dec;
38(15):2690-2705.
PMID: 30538293
ALK mutations occur in 10% of primary neuroblastomas and represent a major target for precision treatment. In combination with MYCN amplification, ALK mutations infer an ultra-high-risk phenotype resulting in very...
13.
Huion A, Decalf V, Kumps C, De Witte N, Everaert K
Acta Clin Belg
. 2018 Aug;
74(4):258-262.
PMID: 30146971
: The objective of the study is to evaluate the use of an experimental smart diaper as an indicator of saturation for diaper change in persons with dementia living in...
14.
Buelens S, Claeys T, Dhondt B, Poelaert F, Vynck M, Yigit N, et al.
Clin Genitourin Cancer
. 2018 Jan;
16(3):197-205.e5.
PMID: 29366632
Background: Resistance mechanisms in the androgen receptor (AR) signaling pathway remain key drivers in the progression to castration-resistant prostate cancer (CRPC) and relapse under antihormonal therapy. Materials And Methods: We...
15.
Claeys S, Denecker G, Cannoodt R, Kumps C, Durinck K, Speleman F, et al.
Oncotarget
. 2018 Jan;
8(63):106820-106832.
PMID: 29290991
Background: Neuroblastoma is an aggressive childhood malignancy of the sympathetic nervous system. Despite multi-modal therapy, survival of high-risk patients remains disappointingly low, underscoring the need for novel treatment strategies. The...
16.
Weynants L, Herve F, Decalf V, Kumps C, Pieters R, De Troyer B, et al.
Int Neurourol J
. 2017 Sep;
21(3):189-196.
PMID: 28954460
Purpose: Clean intermittent self-catheterization (CISC) is now considered the gold standard for the management of urinary retention. In the literature, several articles on patients' perspectives on CISC and adherence to...
17.
Denys M, Decalf V, Kumps C, Petrovic M, Goessaert A, Everaert K
Int J Urol
. 2017 Aug;
24(11):808-815.
PMID: 28815743
Objectives: To explore the mismatch between functional bladder capacity and nocturnal urine production, and to study the pathophysiology of an increased nocturnal urine production in older patients with urinary incontinence....
18.
Claeys T, Lumen N, Kumps C, Praet M, De Meerleer G, Rottey S, et al.
Urol Oncol
. 2017 Feb;
35(4):152.e13-152.e22.
PMID: 28153420
Objectives: To describe the effects of cytoreductive nephrectomy (CN) on the natural course of metastatic renal cell carcinoma (mRCC). CN appears to stabilize metastatic lesions in mRCC in a subgroup...
19.
Decalf V, Huion A, Denys M, Kumps C, Petrovic M, Everaert K
J Am Med Dir Assoc
. 2017 Jan;
18(5):433-437.
PMID: 28108206
Background: Despite the conflicting evidence about postvoid residual (PVR) and its variation in time and corresponding voided volume (VV), studies with urinary diaries and systematic measurements of PVR after each...
20.
Poelaert F, Kumps C, Lumen N, Verschuere S, Libbrecht L, Praet M, et al.
Urol Int
. 2017 Jan;
99(2):222-228.
PMID: 28052297
Objectives: To evaluate the androgen receptor (AR) gene copy number in androgen deprivation therapy (ADT) treatment-naïve prostate cancer (PCa) patients and to evaluate the corresponding AR protein expression and assess...